SIGN UP

March 12, 2020 10:23 AM EDT

CureVac founder back at the helm; Merck extends immunomodulatory drug discovery program with Sutro

Amber Tong

→ Daniel Menichella, the CEO of CureVac and the face of its recent endeavors to develop an mRNA vaccine against Covid-19, is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

view job offer post your job now

TRENDING NOW

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

sponsored

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...